Sunflower Pharmaceutical Reports 8.93% Net Profit Growth in Q1 2026 Despite 18.85% Revenue Decline

Sunflower Pharmaceutical Posts Q1 Results: Profits Grow Against the Trend

36Kr has learned that Sunflower Pharmaceutical (红日药业) recently released its first-quarter 2026 earnings report. The report shows that the company achieved operating revenue of 1.13 billion yuan in Q1 2026, a year-over-year decline of 18.85%. Net profit attributable to shareholders of the listed company reached 65.7148 million yuan, a year-over-year increase of 8.93%, with basic earnings per share of 0.02 yuan.

Notably, despite a significant decline in revenue, Sunflower Pharmaceutical still achieved nearly 9% positive growth in net profit, displaying a clear pattern of rising profits amid declining revenue.

Coexistence of Revenue Decline and Profit Growth

From a financial data perspective, Sunflower Pharmaceutical's Q1 operating revenue dropped 18.85% year-over-year, a rather significant decline. This may be partly related to the overall pressure on the pharmaceutical industry from volume-based procurement policies, and also reflects the challenges the company faces in a competitive market environment.

However, the 8.93% year-over-year growth in net profit attributable to shareholders, reaching 65.7148 million yuan, indicates that the company has made positive progress in cost control and operational efficiency improvements. Achieving profit growth against a backdrop of shrinking revenue demonstrates enhanced profitability and refined management capabilities.

Digital Transformation Becomes Key for the Pharmaceutical Industry

In recent years, Sunflower Pharmaceutical has continued to advance its digital transformation strategy, actively exploring the application of AI technology in drug research and development, smart manufacturing, and supply chain management. Against the backdrop of intensifying competition in the pharmaceutical industry, introducing artificial intelligence and big data analytics tools to optimize production processes and reduce operating costs has become a critical means for pharmaceutical companies to strengthen their core competitiveness.

Industry analysts note that Sunflower Pharmaceutical's pattern of rising profits amid declining revenue this quarter is partly attributable to the continuous optimization of internal operational efficiency, with digital tools and intelligent management systems playing a significant role.

Future Outlook

Looking ahead to the remaining quarters of 2026, Sunflower Pharmaceutical still faces growth pressure on the revenue front. However, the company's demonstrated ability to improve profitability through cost optimization and digital transformation provides a solid foundation for sustainable development. Industry observers will be closely watching whether the company can maintain this profit growth trajectory while stabilizing its revenue base.